These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 38806504)
21. REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma. Caccese M; Desideri I; Villani V; Simonelli M; Buglione M; Chiesa S; Franceschi E; Gaviani P; Stasi I; Caserta C; Brugnara S; Lolli I; Bennicelli E; Bini P; Cuccu AS; Scoccianti S; Padovan M; Gori S; Bonetti A; Giordano P; Pellerino A; Gregucci F; Riva N; Cinieri S; Internò V; Santoni M; Pernice G; Dealis C; Stievano L; Paiar F; Magni G; De Salvo GL; Zagonel V; Lombardi G ESMO Open; 2024 Apr; 9(4):102943. PubMed ID: 38492275 [TBL] [Abstract][Full Text] [Related]
22. Sunitinib with concomitant radiation therapy in inoperable sarcomas: Final results from the dose escalation and expansion parts of a multicenter phase I study. Sunyach MP; Penel N; Montané L; Cassier PA; Largo AC; Sargos P; Blanc E; Pérol D; Blay JY Radiother Oncol; 2022 Mar; 168():95-103. PubMed ID: 35065999 [TBL] [Abstract][Full Text] [Related]
23. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). Soffietti R; Trevisan E; Bertero L; Cassoni P; Morra I; Fabrini MG; Pasqualetti F; Lolli I; Castiglione A; Ciccone G; Rudà R J Neurooncol; 2014 Feb; 116(3):533-41. PubMed ID: 24293233 [TBL] [Abstract][Full Text] [Related]
24. Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513. Brachman DG; Pugh SL; Ashby LS; Thomas TA; Dunbar EM; Narayan S; Robins HI; Bovi JA; Rockhill JK; Won M; Curran WP Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):961-7. PubMed ID: 25832688 [TBL] [Abstract][Full Text] [Related]
25. Temozolomide for high grade glioma. Hart MG; Garside R; Rogers G; Stein K; Grant R Cochrane Database Syst Rev; 2013 Apr; 2013(4):CD007415. PubMed ID: 23633341 [TBL] [Abstract][Full Text] [Related]
26. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. Lai A; Tran A; Nghiemphu PL; Pope WB; Solis OE; Selch M; Filka E; Yong WH; Mischel PS; Liau LM; Phuphanich S; Black K; Peak S; Green RM; Spier CE; Kolevska T; Polikoff J; Fehrenbacher L; Elashoff R; Cloughesy T J Clin Oncol; 2011 Jan; 29(2):142-8. PubMed ID: 21135282 [TBL] [Abstract][Full Text] [Related]
27. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509 [TBL] [Abstract][Full Text] [Related]
28. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Reardon DA; Lassman AB; van den Bent M; Kumthekar P; Merrell R; Scott AM; Fichtel L; Sulman EP; Gomez E; Fischer J; Lee HJ; Munasinghe W; Xiong H; Mandich H; Roberts-Rapp L; Ansell P; Holen KD; Gan HK Neuro Oncol; 2017 Jul; 19(7):965-975. PubMed ID: 28039367 [TBL] [Abstract][Full Text] [Related]
31. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. Herrlinger U; Rieger J; Koch D; Loeser S; Blaschke B; Kortmann RD; Steinbach JP; Hundsberger T; Wick W; Meyermann R; Tan TC; Sommer C; Bamberg M; Reifenberger G; Weller M J Clin Oncol; 2006 Sep; 24(27):4412-7. PubMed ID: 16983109 [TBL] [Abstract][Full Text] [Related]
32. A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma. Fine H; Reid T; Caroen S; Oronsky B; Abrouk N; Butowski N Front Oncol; 2023; 13():1176448. PubMed ID: 37342189 [TBL] [Abstract][Full Text] [Related]
33. Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters. Bag AK; Cezayirli PC; Davenport JJ; Gaddikeri S; Fathallah-Shaykh HM; Cantor A; Han XS; Nabors LB J Neurooncol; 2014 Nov; 120(2):361-70. PubMed ID: 25098699 [TBL] [Abstract][Full Text] [Related]
34. A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma. Morganti AG; Balducci M; Salvati M; Esposito V; Romanelli P; Ferro M; Calista F; Digesù C; Macchia G; Ianiri M; Deodato F; Cilla S; Piermattei A; Valentini V; Cellini N; Cantore GP Int J Radiat Oncol Biol Phys; 2010 May; 77(1):92-7. PubMed ID: 19683876 [TBL] [Abstract][Full Text] [Related]
35. Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. Omuro A; Beal K; McNeill K; Young RJ; Thomas A; Lin X; Terziev R; Kaley TJ; DeAngelis LM; Daras M; Gavrilovic IT; Mellinghoff I; Diamond EL; McKeown A; Manne M; Caterfino A; Patel K; Bavisotto L; Gorman G; Lamson M; Gutin P; Tabar V; Chakravarty D; Chan TA; Brennan CW; Garrett-Mayer E; Karmali RA; Pentsova E J Clin Oncol; 2018 Jun; 36(17):1702-1709. PubMed ID: 29683790 [TBL] [Abstract][Full Text] [Related]
36. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. Clarke JL; Iwamoto FM; Sul J; Panageas K; Lassman AB; DeAngelis LM; Hormigo A; Nolan CP; Gavrilovic I; Karimi S; Abrey LE J Clin Oncol; 2009 Aug; 27(23):3861-7. PubMed ID: 19506159 [TBL] [Abstract][Full Text] [Related]
37. Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study. Chheda MG; Wen PY; Hochberg FH; Chi AS; Drappatz J; Eichler AF; Yang D; Beroukhim R; Norden AD; Gerstner ER; Betensky RA; Batchelor TT J Neurooncol; 2015 Feb; 121(3):627-34. PubMed ID: 25503302 [TBL] [Abstract][Full Text] [Related]
38. Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study. Fabi A; Mirri A; Felici A; Vidiri A; Pace A; Occhipinti E; Cognetti F; Arcangeli G; Iandolo B; Carosi MA; Metro G; Carapella CM J Neurooncol; 2008 Mar; 87(1):79-84. PubMed ID: 17987263 [TBL] [Abstract][Full Text] [Related]
39. A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Nabors LB; Fiveash JB; Markert JM; Kekan MS; Gillespie GY; Huang Z; Johnson MJ; Meleth S; Kuo H; Gladson CL; Fathallah-Shaykh HM Arch Neurol; 2010 Mar; 67(3):313-9. PubMed ID: 20212229 [TBL] [Abstract][Full Text] [Related]
40. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Rosenfeld MR; Ye X; Supko JG; Desideri S; Grossman SA; Brem S; Mikkelson T; Wang D; Chang YC; Hu J; McAfee Q; Fisher J; Troxel AB; Piao S; Heitjan DF; Tan KS; Pontiggia L; O'Dwyer PJ; Davis LE; Amaravadi RK Autophagy; 2014 Aug; 10(8):1359-68. PubMed ID: 24991840 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]